AIM
CTMX icon

Acrospire Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Acrospire Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-637
Closed -$10K – 350
2017
Q2 		$10K Sell
637
-800
-56% -$12.1K 0.01% 1791
2017
Q1 		$25K Buy
+1,437
New +$18.9K 0.02% 1487
2016
Q4 		– Sell
-2,100
Closed -$33K – 2246
2016
Q3 		$33K Buy
+2,100
New +$25.4K 0.02% 1293
2016
Q2 		– Sell
-1,000
Closed -$13K – 2057
2016
Q1 		$13K Buy
+1,000
New +$13.9K 0.01% 1677

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acrospire Investment Management's CTMX Position: Q3 2017 in Review

Acrospire Investment Management sold out of CytomX Therapeutics (CTMX) in Q3 2017, closing a stake of 637 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in CTMX in Q1 2016 and held it in 4 quarters. The position peaked at $33K in Q3 2016. 97 funds tracked by Wall St. Rank hold CTMX as of Q3 2017.

  • Acrospire Investment Management reported no remaining CytomX Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 637 CytomX Therapeutics shares in Q3 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in CytomX Therapeutics in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's CytomX Therapeutics position peaked at $33K in Q3 2016.
  • 97 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.